Bayer's Lab Notebook Is Filling Up. The Earnings Page Is Still Blank Until November 3.
Published on 10/23/2026 at 19:31 | Editorial boerse-global.de
Bayer's drug pipeline and its profit-and-loss account are moving on separate clocks, and investors would do well not to confuse the two. Over the past two weeks the German group has logged a fresh cancer trial, stacked up additional kidney-disease data and cleared a regulatory filing past the US gatekeeper. None of that tells you what the company will earn this year. That answer arrives on November 3, when Bayer publishes its third-quarter 2026 report.
A first patient, not a result
Vividion Therapeutics, the Bayer subsidiary, said on October 15 that the first patient had been dosed in a global Phase II study. The trial pairs VVD-214 with pembrolizumab in previously untreated patients with advanced colorectal cancer whose tumours carry MSI-high or dMMR markers. That is a tightly defined population, and the announcement marks the start of treatment rather than any readout on efficacy. It should not be filed alongside positive study data, because it isn't.
The same discipline applies to Finerenone, where the news is of a different order. New analyses of the FIND-CKD trial — testing the drug in chronic kidney disease without diabetes — showed consistent effects on proteinuria and on loss of kidney function across patient subgroups, according to Bayer, which presented the work at ASN Kidney Week. These are fresh readings from a study already run, not the launch of a new one. Roughly two weeks earlier, the FDA accepted the company's supplemental application for that use, again on the strength of FIND-CKD. Acceptance is a procedural step; it is not an approval.
What the sell side is actually saying
Against that clinical backdrop, the analyst community has been holding its ground rather than shifting it. JPMorgan reaffirmed an "Overweight" rating on October 16 with a price target of 61 euros; analyst Richard Vosser put revenue 2% above consensus. UBS kept its "Buy" call and a 62-euro target a day earlier, on October 15. Neither move was an upgrade, and neither constitutes proof that the business is improving — a target price can express a long-run view while the next set of figures exposes the near-term risk to earnings.
Should investors sell immediately? Or is it worth buying Bayer?
That distinction matters because the estimate trend has been running the other way. Media reports on October 13 indicated that analyst forecasts for Bayer's earnings per share had fallen since the start of August. Earnings per share therefore becomes the number to watch: the question is not simply what Bayer reports, but whether it underpins the already-lowered bar or signals that further cuts are needed. Beating a reduced estimate is not the same thing as improving on earlier periods, and the two should never be treated as equivalent.
The farm side is sending its own signal
Pressure from agriculture complicates the bull case. FMC cut its outlook sharply on October 15, and the warning weighed on Bayer shares according to media reports — though it is impossible to read across the size of any hit to Bayer, or to explain every subsequent share-price move, from that single announcement. The broader European farming backdrop is no easier. A study commissioned by Bayer, reported about a week ago, found that output growth in the EU and the UK is trailing major agricultural markets, with geopolitical and climatic strains sharpening the challenge.
None of this proves a specific earnings miss at Bayer. It does argue against assuming that conditions in agriculture will ease without evidence — and it means the bear case has to take seriously the possibility that reduced expectations are not yet a floor. A single disappointing metric is one thing; a continuing slide in forecasts is another.
Two scenarios, one date
The optimistic path starts with expectations simply holding steady. If Bayer's numbers underpin the lowered forecasts, the constructive analyst stance gains weight, and the worry that investors must again mark down their assumptions begins to fade. That would be the precondition for giving longer-term development prospects more room in the valuation. It would not, on its own, amount to a full operational turnaround.
Bayer at a turning point? This analysis reveals what investors need to know now.
The pessimistic path is just as concrete. Should earnings momentum weaken further, upbeat price targets would offer little shelter, and the central danger would be not one weak line item but a renewed downward drift in estimates.
Either way, the operative sequence for investors runs from the business to the expectations built on it, and only then to whether the bullish ratings look convincing. A price target by itself settles nothing. The November 3 quarterly statement is where the market finds out which scenario carries more weight — and whether the science moving through Bayer's labs can finally be matched by a steadier earnings trajectory.
Ad
Bayer Stock: New Analysis - 23 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
